Adipose Cell Secretions for Remote Injection and Cryopreservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating inflammatory conditions, ligament and tendon injuries, and compositions for intensive animal farming are limited by the need for direct administration of adipose tissue-derived cell suspensions or secretions to affected areas, and there is a lack of effective methods for cryopreserving stem cells without culturing after thawing.
Innovation Solution
The use of adipose tissue-derived cell secretions or suspensions, optionally comprising adipocytes, for remote administration via subcutaneous or intramuscular injection, and the storage of cells with cell-derived secretions to improve viability and proliferation potential, allowing for effective treatment of inflammatory disorders, ligament and tendon injuries, and prevention of diseases in intensively farmed animals without the need for direct application or prior culturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adipose tissue-derived cell suspensions are administered directly to affected areas, then therapeutic efficacy is improved, but ease of operation deteriorates due to invasive procedures required
Solution Approach 1:
The patent uses an adipose tissue-derived cell-free secretion composition as an intermediary substance that can be administered remotely (e.g., via intramuscular or subcutaneous injection) to achieve therapeutic effects without requiring direct injection into the affected area. This mediator carries therapeutic factors that travel to the target site, resolving the contradiction between efficacy and ease of administration.
2Ease of manufacture
If stem cells are cryopreserved without cell-derived secretions, then storage simplicity is improved, but viability and proliferation potential deteriorate after thawing
Solution Approach 1:
The patent applies preliminary action by incorporating cell-derived secretions into the cryopreservation medium before freezing. These secretions (including growth factors, cytokines, and extracellular matrix components) are pre-added to protect cells during freezing and to enhance their viability and proliferative capacity after thawing, thus resolving the contradiction between storage simplicity and cell viability.
3Manufacturing precision
If adipose tissue is processed to isolate non-adipocyte cells, then stem cell purity is improved, but manufacturing complexity deteriorates due to enzymatic digestion and centrifugation steps
Solution Approach 1:
The patent extracts only the necessary therapeutic component (cell-free secretions) from the adipose tissue without requiring complete isolation and purification of stem cells. By taking out the secretory products directly from cultured adipose-derived cells and using this cell-free composition, the method achieves therapeutic efficacy while significantly simplifying the manufacturing process and avoiding complex enzymatic digestion and centrifugation steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Remote administration of adipose tissue-derived cell secretions or suspensions effectively treats inflammatory disorders and injuries, and improves the viability and therapeutic efficacy of cryopreserved stem cells, providing a non-invasive and efficient treatment option for both human and animal subjects, including those in intensive farming scenarios.
Implementation Method 1
compositions comprising (i) adipose tissue-derived cell secretions
Implementation Method 2
improved methods, agents and compositions for cryopreservation of cells
Data Source
Figure 1
Figure 2
Figure 3~5
AI summary
The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.